

**PATENT**

**CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on June 2, 2006.

6/2/06 Michelle Hobson  
Date Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:	Examiner:
Jo MILNER	Group Art Unit:
Serial No.: 10/549,711	Confirmation No.: 2196
International Appl. No. PCT/GB2004/001128	Customer No.: 20855
International Filing Date: 17 March 2004	
Title: REGULATION OF GENE EXPRESSION	

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,  
Applicant(s) hereby submits the following information in conformance with 37 C.F.R.  
§§1.97 and 1.98.

- ☐ Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- ☐ No copies of the publications \_\_\_\_\_ listed on the attached Form PTO/SB/08A are being provided because the Office waives the requirement under 37 C.F.R. 1.98 (a) (2) (i) for submitting a copy of each cited U.S. patent and each U. S. patent application publication for all U.S. national patent applications filed after June 30, 2003.
- ☐ No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. \_\_\_\_ to which the above-identified application claims priority under 35 U.S.C. §120.

- ☒ Publication(s) A1, B1-B3 and C1-C5 listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to PCT/GB2004/001128 and mailed on November 11, 2004.
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. English language publication \_\_\_\_ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed is an explanation of non-English publication(s) \_\_\_\_\_ for which an English translation is not available.
- ☐ Enclosed is an English translation of non-English publication(s) \_\_\_\_\_ cited in the attached Form PTO/SB/08A.
- ☐ Enclosed is a copy of pending patent Application Serial No. \_\_\_\_\_.


This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Date: June 2, 2006

By:   
Dahna S. Pasternak  
Registration No. 41,411

ROBINS & PASTERNAK LLP  
1731 Embarcadero Road, Suite 230  
Palo Alto, CA 94303  
Tel.: (650) 493-3400  
Fax: (650) 493-3440

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
		Application Number		10/549,711	
		Int'l Filing Date		17 March 2004	
		First Named Inventor		Jo MILNER	
		Group Art Unit			
		Examiner Name			
Sheet	1	of	1	Attorney Docket Number 4100-0001	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	A1	6,414,134	B1	Reed	07-02-2002

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		
	B1	WO	02/055692	A2	RIBOPHARMA	07-18-2002
	B2	WO	03/040366	A2	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	05-15-2003
	B3	WO	03/070969	A2	RIBOZYME PHARMACEUTICALS, INC.	08-28-2003

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C1	Cioca et al., "RNA INTERFERENCE IS A FUNCTIONAL PATHWAY WITH THERAPEUTIC POTENTIAL IN HUMAN MYELOID LEUKEMIA CELL LINES," Cancer Gene Therapy 10:125-133 (2003)
	C2	Gautschi et al., "ACTIVITY OF A NOVEL BCL-2/BCL-XL-BISPECIFIC ANTISENSE OLIGONUCLEOTIDE AGAINST TUMORS OF DIVERSE HISTOLOGIC ORIGINS," Journal of the National Cancer Institute 93:465-471 (2001)
	C3	Jiang, et al., "BCL-2 CONSTITUTIVELY SUPPRESSES P53-DEPENDENT APOPTOSIS IN COLORECTAL CANCER CELLS," Genes & Development 17:832-8327 (2003)
	C4	Takashi et al., "INDUCTION OF APOPTOSIS IN HELA CELLS WITH SIRNA EXPRESSION VECTOR TARGETED AGAINST BCL-2," Nucleic Acids Research Supplement Abstract only (2001)
	C5	Wacheck et al., "SMALL INTERFERING RNA TARGETING BCL-2 SENSITIZES MALIGNANT MELANOMA," Oligonucleotides 13:393-400 (2003)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.